The Talent Challenge in Biologics Manufacturing
Executive Summary
While companies are working hard to create new manufacturing capacity for biologics, protein production, which requires more highly trained and experienced workers, will remain constrained by a lack of qualified staff. Companies will need to act on a variety of fronts to deal with the problem--among them, more co-op hiring, and more partnering with companies with the requisite manufacturing capacity.
You may also be interested in...
Expert Warns Of Looming 'Capacity Crunch' For New Cell And Gene Therapy Products
Capacity shortages are looming for manufacturers wanting to develop and commercialize cell and gene therapy products over the next five years, an industry survey shows. The key finding: these firms should quickly build and staff the manufacturing facilities they will need.
Compound Therapeutics Inc.
Compound Therapeutics has engineered proteins, called Adzymes, which bind to targets with the specificity of antibodies but unlike them destroy their targets using an attached enzyme.
Compound Therapeutics Inc.
Compound Therapeutics has engineered proteins, called Adzymes, which bind to targets with the specificity of antibodies but unlike them destroy their targets using an attached enzyme.